59
Treatment guidelines say patients who undergo minimally invasive aortic heart valve replacements should receive two antiplatelet drugs to reduce the risk of dangerous blood clots. A new study has found that a single antiplatelet drug may work just as well, with lower risks of life-threatening bleeding and other complications.